Purpose We review recent advances in the biologic understanding and treatment of
childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), identify …

Adolescents and young adults (AYA) with cancer have been designated as a vulnerable
population by the National Cancer Institute. This group, defined by the ages of 16-39 years …

Summary The Medical Research Council Acute Myeloid Leukaemia 12 (MRC AML12) trial
(children) addressed the optimal anthracenedione/anthracycline in induction and the …

Purpose To evaluate the early treatment response in children with acute myeloid leukemia
(AML) using a response-guided induction strategy that includes idarubicin in the first course …

Background Several studies of pediatric acute myeloid leukemia have described the various
type-I or type-II aberrations and their relationship with clinical outcome. However, there has …

Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of
pediatric acute myeloid leukemia - PMC Back to Top Skip to main content NIH NLM Logo Access …

BACKGROUND: The objectives of this study were to describe the incidence, timing, and
predictors of treatment‐related mortality (TRM) among children with acute lymphoblastic …

Mutations in the NADP+-dependent isocitrate dehydrogenase genes 1 and 2 (IDH1 and
IDH2) have recently been found in adult acute myeloid leukemia (AML) patients with a …

We previously demonstrated that outcome of pediatric 11q23/MLL-rearranged AML depends
on the translocation partner (TP). In this multicenter international study on 733 children with …

Background: Cancer is the second most common cause of death in children in the
developed world. The study investigated patterns and trends in survival from childhood …